BW universe: US & CA common stocks only · ETFs and mutual funds excluded · Methodology →
Price chart with forecast cone and smart-money events
Wall Street Analyst Consensus
Wall Street Analyst Consensus
Aggregate of 6 third-party analyst opinions — not Quantellect advice.
12-mo median price target
$201
6 Wall St 12-month targets
High
$266
Average
$202
Low
$132
Recent price history, then Wall-Street analysts’ 12-month price targets (high / median / low) shown forward to the 12-month target levels. Targets are third-party analysts’ estimates of future performance — not guarantees, and not Quantellect recommendations. Past results do not guarantee future returns.
Per-analyst ratings are not yet available for this ticker.
Aggregate of third-party analysts’ published opinions, shown for information only — not Quantellect advice. The 75/100 Analyst Score (Strong Buy) is Quantellect’ documented weighting of the rating distribution on the same 0–100 scale as the Tide / Squeeze / Trend / Money scores; the verdict label is derived from that score. Past results do not guarantee future returns. Source: aes.
Not investment advice. Past results do not guarantee future returns. Scores, narratives, and historical-cohort statistics on this page are generated by Quantellect algorithms from public filings, market data, and AI synthesis, and describe the historical performance of structurally similar setups in our universe; failures are included. Data may be 15-minute delayed, contain errors, or be revised. Always do your own research and consult a licensed financial advisor before making investment decisions.
BW analyst · the story · Today
Today story being generated
The BW analyst hasn't produced a story for this ticker yet — both
today and outlook clocks are pending. Check back shortly; the Phase
3 LLM pipeline refreshes both clocks on a rolling cadence.
Not investment advice. Generated by AI from BW data layers. May contain errors or hallucinations. Always do your own research.
Price, smart-money events, and how similar setups behaved in the past
Latest PRBelite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
Top storyBelite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
